Abstract
Introduction. Cancer patients have a high risk of developing venous thromboembolic complications, which worsen the outcomes of antitumor treatment and are the second leading cause of death after cancer progression.
Objectives – to assess the effect of modern anticoagulants (LMWH and DOAC) on the hemostasis system and the incidence of thrombotic complications in patients with Hodgkin’s lymphoma.
Material and methods. The hemostasis system and the incidence of thrombotic complications were studied in 90 patients with Hodgkin’s lymphoma receiving antitumor drug therapy. Patients in group I (n=36) did not receive drug prophylaxis of thrombotic complications. Patients in group II (n=44) received DOAC or LMWH The hemostasis system was studied in patients with thrombosis (n=10). Patients received therapeutic doses of anticoagulants.
Results. Patients with Hodgkin’s lymphoma have hypercoagulation with signs of chronic intravascular coagulation even before the start of treatment. The use of anticoagulants in patients with Hodgkin’s lymphoma receiving antitumor drug therapy reduces the activation of intravascular coagulation and the incidence of venous thrombosis. In the group of patients who did not receive drug prophylaxis, the incidence of thrombotic complications was 8 cases, in the group of patients receiving anticoagulants – 2 cases. The use of therapeutic doses of anticoagulants in patients with thrombosis led to a decrease in the concentration of fibrinogen, fibrin monomer and D-dimer. According to ultrasound imaging, venous thrombosis was not detected, or recanalization of the vessel lumen occurred, in no case did PE develop.
Conclusion. Modern anticoagulants reduce the intensity of intravascular blood coagulation and are an effective and safe means for the treatment and prevention of venous thrombosis in patients with Hodgkin’s lymphoma.
Keywords
Authors and affiliations
https://elibrary.ru/ucveji
O.V. Somonova(1),A.L. Elizarova(1), A.V. Vardanyan(2)
1-Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” Ministry of Health
of the Russian Federation, Kashirskoe shosse, 24, Moscow, 115522, Russian Federation; 2-Federal State Budgetary
Educational Institution of Additional Professional Education “Russian Medical Academy of Continuous Professional Education”
Ministry of Health of the Russian Federation, Barrikadnaya st., 2/1, building 1, Moscow, 125993, Russian Federation
References
Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb. Haemost. 2017; 117 (2): 219–30. DOI: 10.1160/TH16-08-061.
Falanga A., Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J. Thromb. Haemost. 2023; 21 (6): 1397–408. DOI: 10.1016/j.jtha.2023.02.029.
Gran O.V., Braekhan S.K., Hansen J.B. Prothrombotic genotypes and risk of venous thromboembolism in cancer. Thromb. Res. 2018; 164 (1): 12–8. DOI: 10.1016/j.thromres.2017.12.025.
Kirkizlar O., Kirkizlar T.A., Umit E.G. et al. The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia, 2020; 20 (8): 542–7. DOI: 10.1016/j.clml.2020.02.021.
Rupa-Matysek J., Gil L., Kazmierczak M. et al. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. Med. Oncol. 2017; 35 (1): 5. DOI: 10.1007/s12032-017-1065-4.
Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: biological and clinical aspects // J. Thromb. Haemost. 2013; 11 (2): 223–33. DOI: 10.1111/jth.12075.
Shao B.Z., Yao Y., Li J.P. et al. The role of neutrophil extracellular traps in cancer. Front. Oncol. 2021; 11: 714357. DOI: 10.3389/fonc.2021.714357.
Posch F., Riedl J., Reitter E.F. Hypercoagulability, venous thromboembolism, and death in patients with cancer. A Multi-State Model. J. Thrombosis Haemostasis. 2016; 115 (40): 817–26. DOI: 10.1160/TH15-09-0758.
Андрияшкин В.В., Сомонова О.В., Пантелеев М.А., Варданян А.В., Золотухин И.А., Явелов И.С., Гладков О.А., Леонтьев С.Г., Кириенко А.И., Поддубная И.В. Диагностика, лечение и профилактика тромбоэмболических осложнений у онкологических и онкогематологических больных. Учебное пособие, М.: ФГБОУ ДПО РМАНПО Минздрава России, 2017; 76. ISBN 978-5-7249-2842-7. [Andriashkin V.V., Somonova O.V., Panteleev M.A., Vardanyan A.V., Zolotukhin I.A., Yavelov I.S., Gladkov O.A., Leontiev S.G., Kirienko A.I., Poddubnaya I.V. Diagnosis, Treatment, and Prevention of Thromboembolic Complications in Cancer and Hematological Patients. Textbook, Moscow: Russian Medical Academy of Continuous Professional Education, 2017; 76. ISBN 978-5-7249-2842-7 (in Russian)].
Falanga A., Ay C., Di Nisio M. et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline(dagger). Ann. Oncol. Published online January 10. 2023. DOI: 10. 1016/j.annonc.2022.12.014.
Farge D., Frere C., Connors J.M. et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022; 23 (7): e334-e47. DOI: 10.1016/S1470-2045(22)00160-7.
Ageno W., Vedovati M.C., Cohen A. et al. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study. J. Thrombosis and Haemostasis. 2021; 121 (5): 616–24. DOI: 10.1055/s-0040-1720975.
Young A.M., Marshall A., Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J. Clin. Oncol. 2018; 36 (20): 2017. DOI: 10.1200/JCO.2018.78.8034.
Streiff M.B., Holmstrom B., Angelini D. et al. Cancer-associated venous thromboembolic disease, Version 2.2024. NCCN Clinical Practice Guidelines in Oncology. 2024; 22 (7): 483–506.
. Carrier M., Abou-Nassar K., MallickR. et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N. Engl. J. Med. 2019; 380 (8): 711–9. DOI: 10.1056/NEJMoa1814468.
Khorana A.A., Soff G.A., Kakkar A.K. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N. Engl. J. Med. 2019; 380 (8): 720–8. DOI: 10.1056/NEJMoa1814630.
Otasevic V., Mihaljevic B., Milic N. et al. Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J. 2022; 20: 20. DOI: 10.1186/s12959-022-00381-3.
Otten H.M., Mathijssen J., ten Cate H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch. Inter. Med. 2004; 164 (2): 190–4. DOI: 10.1160/TH05-10-0694.